Dyne Therapeutics (DYN) Long-Term Debt Issuances (2020 - 2025)
Dyne Therapeutics (DYN) recorded quarterly Long-Term Debt Issuances of $49.5 million in Q4 2025, up 397.73% quarter-over-quarter from $9.9 million in Q1 2020.
Dyne Therapeutics (DYN) Long-Term Debt Issuances (2020 - 2025) Analysis & Trends
Dyne Therapeutics' Long-Term Debt Issuances history runs 2 years deep, the most recent figure standing at $49.5 million for Q4 2025.
- In Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to $49.5 million; the TTM figure through Dec 2025 stood at $49.5 million (changed N/A YoY), while the FY2025 annual figure was $148.3 million, changed N/A from the prior year.
- Long-Term Debt Issuances was $49.5 million for Q4 2025 at Dyne Therapeutics, up from $9.9 million in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $49.5 million in Q4 2025 to a low of $49.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 2.73 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Dyne Therapeutics | 3.00 Bn | 3.00 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 49.45 Mn |
| Dec 31, 2025 | 49.45 Mn |
| Mar 31, 2020 | 9.94 Mn |
| Mar 31, 2020 | 9.94 Mn |